ArticleInternational journal of clinical and experimental pathology2026
High levels of P2RX5 expression predicts a poor prognosis and promotes tumor progression in endometrial cancer.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the impact of P2RX5 on the clinical pathological characteristics and prognosis of endometrial carcinoma, and to explore its potential underlying mechanisms.
methodsThe clinical samples, including 150 specimens with endometrial carcinoma (Case group) and 100 endometrial samples without cancer (Control group), were collected for analyzing the amount of P2RX5 expression. Cell biology experiments were also used for exploring the effects of P2RX5 expression on biological behaviors of endometrial carcinoma.
resultsThe results showed that P2RX5 expression in endometrial carcinoma tissues were significantly higher than in endometrial tissues from the control group. Additionally, expression levels showed a positive correlation with tumor size, differentiation grade, and tumor stage, with risk values of 3.57, 6.07, and 9.78, respectively. This increase in risk was statistically significant (
conclusionThese findings suggest a critical role of P2RX5 in endometrial cancer progression and thereby establish the value of P2RX5 as a prognostic biomarker and provide a promising therapeutic target for endometrial cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.